The biotech industry’s growth translates into huge returns for commercial real estate—if you know where to invest, says $1T asset manager Taimur Hyat.
Hyat is the chief strategy officer for Prudential Financial’s asset-management arm, and he says biotech is causing a revolutionary change in real estate opportunities as labs and offices are sticky, long-term investments due to the demand for space, Bloomberg reports.
Due to the rapid growth in the industry, Hyat says commercial real estate in biotech markets from Boston to Shanghai to Munich are attractive investments. And biotech is booming—the Nasdaq Biotechnology Index has surged 182% from the end of 2010 while the S&P 500 Index climbed 64% over that time.
Hyat also says senior housing is a good investment in the US, although some fear it will soon be overbuilt. [Bloomberg]
News
Sign up for more articles like this
Subscribe to Bisnow's National Newsletters
Related Stories
